BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

62 related articles for article (PubMed ID: 38565963)

  • 1. Mitotic catastrophe and cell cycle arrest are alternative cell death pathways executed by bortezomib in rituximab resistant B-cell lymphoma cells.
    Gu JJ; Kaufman GP; Mavis C; Czuczman MS; Hernandez-Ilizaliturri FJ
    Oncotarget; 2017 Feb; 8(8):12741-12753. PubMed ID: 28055975
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinically relevant GABARAP deficiency abrogates bortezomib-induced immunogenic cell death in multiple myeloma.
    Zhao L; Shen Z; Kroemer G; Kepp O
    Oncoimmunology; 2024; 13(1):2360275. PubMed ID: 38812570
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Radiation therapy: An old dog learning new tricks.
    Sato A; Kraynak J; Marciscano AE; Galluzzi L
    Methods Cell Biol; 2022; 172():xiii-xxiii. PubMed ID: 36064230
    [No Abstract]   [Full Text] [Related]  

  • 4. Progress on the Application of Bortezomib and Bortezomib-Based Nanoformulations.
    Liu J; Zhao R; Jiang X; Li Z; Zhang B
    Biomolecules; 2021 Dec; 12(1):. PubMed ID: 35053199
    [TBL] [Abstract][Full Text] [Related]  

  • 5. B-Myb deficiency boosts bortezomib-induced immunogenic cell death in colorectal cancer.
    Hui YJ; Yu TT; Li LG; Peng XC; Di MJ; Liu H; Gu WL; Li TF; Zhao KL; Wang WX
    Sci Rep; 2024 Apr; 14(1):7733. PubMed ID: 38565963
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combined bortezomib-based chemotherapy and p53 gene therapy using hollow mesoporous silica nanospheres for p53 mutant non-small cell lung cancer treatment.
    Li C; Hu J; Li W; Song G; Shen J
    Biomater Sci; 2016 Dec; 5(1):77-88. PubMed ID: 27822577
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Effect of Phase Transition Temperature on Therapeutic Efficacy of Liposomal Bortezomib.
    Korani M; Nikoofal-Sahlabadi S; Nikpoor AR; Ghaffari S; Attar H; Mashreghi M; Jaafari MR
    Anticancer Agents Med Chem; 2020; 20(6):700-708. PubMed ID: 31893998
    [TBL] [Abstract][Full Text] [Related]  

  • 8. BCMA-targeted bortezomib nanotherapy improves therapeutic efficacy, overcomes resistance, and modulates the immune microenvironment in multiple myeloma.
    Dutta D; Liu J; Wen K; Kurata K; Fulciniti M; Gulla A; Hideshima T; Anderson KC
    Blood Cancer J; 2023 Dec; 13(1):184. PubMed ID: 38072962
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Proteasome Inhibitor Bortezomib Induces p53-Dependent Apoptosis in Activated B Cells.
    Ochoa TA; Rossi A; Woodle ES; Hildeman D; Allman D
    J Immunol; 2024 Jan; 212(1):154-164. PubMed ID: 37966267
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bortezomib-loaded mixed micelles realize a "three-in-one" effect for enhanced breast cancer treatment.
    Liu J; Xu X; Li Y; Xu J; Zhao R; Liu S; Wu J; Zhang L; Zhang B
    Biomater Sci; 2023 Jul; 11(14):4890-4906. PubMed ID: 37306225
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Modulating the tumor immune microenvironment with nanoparticles: A sword for improving the efficiency of ovarian cancer immunotherapy.
    Xu T; Liu Z; Huang L; Jing J; Liu X
    Front Immunol; 2022; 13():1057850. PubMed ID: 36532066
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combined Effect of Healthy Lifestyle Factors and Risks of Colorectal Adenoma, Colorectal Cancer, and Colorectal Cancer Mortality: Systematic Review and Meta-Analysis.
    Yu J; Feng Q; Kim JH; Zhu Y
    Front Oncol; 2022; 12():827019. PubMed ID: 35936678
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The p53 network: cellular and systemic DNA damage responses in cancer and aging.
    Vaddavalli PL; Schumacher B
    Trends Genet; 2022 Jun; 38(6):598-612. PubMed ID: 35346511
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Children's Oncology Group Trial AALL1231: A Phase III Clinical Trial Testing Bortezomib in Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia and Lymphoma.
    Teachey DT; Devidas M; Wood BL; Chen Z; Hayashi RJ; Hermiston ML; Annett RD; Archer JH; Asselin BL; August KJ; Cho SY; Dunsmore KP; Fisher BT; Freedman JL; Galardy PJ; Harker-Murray P; Horton TM; Jaju AI; Lam A; Messinger YH; Miles RR; Okada M; Patel SI; Schafer ES; Schechter T; Singh N; Steele AC; Sulis ML; Vargas SL; Winter SS; Wood C; Zweidler-McKay P; Bollard CM; Loh ML; Hunger SP; Raetz EA
    J Clin Oncol; 2022 Jul; 40(19):2106-2118. PubMed ID: 35271306
    [TBL] [Abstract][Full Text] [Related]  

  • 15.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 16.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 17.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.